Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 5
Submit an article Journal homepage
154
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients

Benedetta Dalla PalmaDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information
,
Fabrizio AccardiDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information
,
Lucia PreziosoHematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information
,
Laura NotarfranchiDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information
&
Nicola GiulianiDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-3457-3774View further author information
ORCID Icon
Pages 1238-1241 | Received 07 Aug 2019, Accepted 10 Dec 2019, Published online: 06 Jan 2020

References

  • Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica. 2018;103(2):197–211.
  • Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99:731–735.
  • Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol. 2005;130(4):588–594.
  • Harousseau J-L, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139–3146.
  • Lahuerta J-J, Paiva B, Vidriales M-B, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. JCO. 2017;35(25):2900–2910.
  • errot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464.
  • Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377–2380.
  • Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood. 2010;115(1):32–37.
  • Biran N, Rowley SD, Vesole DH, et al. A phase I/II study of escalating doses of bortezomib in conjunction with high-dose melphalan as a conditioning regimen for salvage autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2016;22(12):2165–2171.
  • Aypar E, İzzettin FV, Akı ŞZ, et al. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. J Oncol Pharm Pract. 2018;24(4):281–289.
  • Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010;16(20):5079–5086.
  • Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant. Leuk Lymphoma. 2016;57(4):973–976.
  • Roussel M, Hebraud B, Lauwers-Cances V, et al. Bortezomib and high-dose melphalan vs. high-dose melphalan as conditioning regimen before autologous stem cell transplantation in de novo multiple myeloma patients: a phase 3 study of the Intergroupe Francophone Du Myelome (IFM 2014-02). Blood. 2017;130:398.
  • Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
  • Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
  • Thompson PA, Prince HM, Seymour JF, et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant. 2011;46(5):764–765.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.